



TML: CS: 2017-18:

10th May, 2017

To
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001

National Stock Exchange of India Ltd.
"Exchange Plaza",
Bandra – Kurla Complex,
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Meeting Commencement time : 11:45 A.M.
Meeting Conclusion Time : 4:35 P.M.

The Board of Directors at its meeting held today, perused and approved the following matters:

1. Approved the Audited Standalone and Consolidated financial results for the Quarter and Year ended 31st March, 2017.
A copy of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2017 is enclosed herewith.
2. Approved Draft Directors' Report for the year ended 31st March, 2017.
3. Approved Draft Secretarial Audit Report issued by Mr. Shirish Shetye, Practicing Company Secretary for the financial year ended 31st March, 2017.
4. Considered the matter of rotational appointment of Statutory Auditors of the Company and decided to take decision in this regard at appropriate time.
5. Confirmed the time, date and venue of the 47th Annual General Meeting which will be held on Wednesday, 27th September, 2017 at the Registered Office of the Company.
6. Approved Draft Notice of 47th Annual General Meeting to be sent to the members.
7. Allotment of 4929 Equity shares to eligible employees' pursuant exercise of ESOP options under Themis ESOS Scheme 2012.
8. Appointed Mr. Shirish Shetye as the Scrutinizer for conducting E-Voting and for conducting Polling at the 47th Annual General Meeting.
9. Reconstituted Audit & Risk Management Committee by appointing Dr. Sachin D. Patel as the members of the Committee in place of Dr. Dinesh S. Patel.



Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India

Tel. : 91-22-6760 7080 • Fax : 91-22-6760 7070 / 2874 6621

Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.

CIN No.: L24110GJ1969PLC001590 • Tel / Fax No.: Regd. Off. : 0260 2431447 / 2430219

• E-mail : themis@themismedicare.com • Website : www.themismedicare.com

As reported in the attached Independent Auditor's Report "The Financial Results include the Results for the quarter ended March 31, 2017 being the balancing figures between the audited figures in respect of the full financial year and the published year to date unaudited figures up to the third quarter of the current financial year which were subjected to limited review by the Statutory Auditors.

This may be taken as compliance under the Listing Regulations.

Kindly acknowledge.

Thanking you,
Yours faithfully,

For THEMIS MEDICARE LIMITED



PRAKASH D. NARINGREKAR
COMPANY SECRETARY



M. T. ANKLESHWARIA & CO.
CHARTERED ACCOUNTANTS
MADHU T. ANKLESHWARIA
B.COM. (HONS) F.C.A.

TEL: 2614 9392
7 GOKUL NIWAS,
47, BAJAJ ROAD,
VILE PARLE (WEST),
MUMBAI - 400 056
mtankleshwaria@yahoo.com

Independent Auditor's Report

To
Board of Directors of
THEMIS MEDICARE LIMITED
Mumbai

1. We have audited the accompanying statement of **Standalone Financial Results** of Themis Medicare Limited (the 'Company') for the year ended 31st March, 2017 (the 'Financial Results'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These Financial Results, which are the responsibility of the company's management and approved by the Board of Directors, have been prepared on the basis of the related financial statements which is in accordance with the Accounting Standards, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on these Financial Results.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Financial Results are free of material misstatement(s).
An audit includes performing procedure to obtain audit evidence about the amounts and the disclosures in the Financial Results. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the Financial Results, whether due to fraud or error. In making in those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Financial Results in order to design the Audit Procedure that are appropriate in the circumstances, but not for the purpose expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Financial Results.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



3. In our opinion and to the best of our information and according to the explanations given to us the Financial Results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the Net Profits and other financial information of the Company for the year ended March 31, 2017.

4. The Financial Results include the Results for the quarter ended March 31, 2017 being the balancing figures between the audited figures in respect of the full financial year and the published year to date unaudited figures up to the third quarter of the current financial year which were subject to limited review by us.

For **M.T.ANKLESHWARIA & CO,**
CHARTERED ACCOUNTANTS
Registration No. 100501W



[Signature]
MADHU T. ANKLESHWARIA
PROPRIETOR
Membership No. 30128

Place: Mumbai
Date: 10.05.2017

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

PART I (R in Lakhs)

Statement of Audited Financial Results for the year ended 31st March 2017.

		STANDALONE				
	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Current Year ended	Previous Year ended
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	4,898.82	5,444.42	4,445.35	21,665.92	20,289.26
II	Other Income	32.05	18.77	51.22	279.94	273.62
III	Total Revenue (I + II)	4,930.87	5,463.19	4,496.57	21,945.86	20,562.88
IV	Expenses :					
	(a) Cost of materials consumed	1,291.18	1,441.54	1,395.62	5,653.28	6,278.36
	(b) Purchases of stock-in-trade	467.99	517.16	342.50	2,004.38	1,375.82
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(496.67)	106.61	(89.65)	(382.56)	171.10
	(d) Employee benefits expense	1,036.22	976.71	708.07	4,017.88	3,191.22
	(e) Finance Costs	269.86	260.69	312.89	1,088.16	1,216.41
	(f) Depreciation and amortisation expense	170.99	170.68	186.53	680.53	747.03
	(g) Other expenses	1,941.04	1,770.20	1,456.05	7,184.14	6,130.44
	Total expenses	4,680.61	5,243.59	4,312.01	20,245.81	19,110.38
V	Profit / (Loss) before exceptional and extraordinary items and tax (III-IV)	250.26	219.60	184.56	1,700.05	1,452.50
VI	Exceptional items	-	-	-	-	-
VII	Profit / (Loss) before extraordinary items and tax (V-VI)	250.26	219.60	184.56	1,700.05	1,452.50
VIII	Extraordinary items	-	-	-	-	-
IX	Profit / (Loss) before tax (VII-VIII)	250.26	219.60	184.56	1,700.05	1,452.50
X	Tax expense :					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	(13.50)	(13.50)	(53.99)	(53.99)	(53.99)
XI	Profit / (Loss) for the period (IX-X)	263.76	233.10	238.55	1,754.04	1,506.49
XII	Earnings per share					
	(a) Basic	2.92	2.58	2.80	19.40	17.69
	(b) Diluted	2.84	2.51	2.78	18.91	17.55



PART II

Information for the year ended 31/03/2017

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended	Current Year ended	Previous Year ended
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding	2984138	2976005	2459705	2984138	2459705
	- Number of shares	33.01	32.95	28.89	33.01	28.89
	- Percentage of shareholding					
2	Promoters and Promoter Group Shareholding					
	a) Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL
	- Number of shares					
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
	b) Non - encumbered	6055295	6055295	6055295	6055295	6055295
	- Number of shares					
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	66.99	67.05	71.11	66.99	71.11

	Particulars	3 months ended (31/03/2017)
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-



THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

R IN LAKHS

Statement of Assets and Liabilities as at 31st March 2017		STANDALONE	
	Particulars	As at 31/03/2017	As at 31/03/2016
		(Audited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds	903.94	851.50
	(a) Share capital	9,818.92	5,579.21
	(b) Reserves and surplus	156.25	0.00
	(c) Amount Received against ESOP	10,879.11	6,430.71
	Sub-total - Shareholders' Funds		
2	Non-current Liabilities	1,366.27	3,044.67
	(a) Long-term borrowings	76.08	130.07
	(b) Deferred tax liabilities (net)	443.49	382.49
	(c) Other long-term liabilities	1,885.84	3,557.23
	Sub-total - Non-current Liabilities		
3	Current Liabilities	5,409.30	5,188.42
	(a) Short-term borrowings	3,163.33	3,252.52
	(b) Trade payables	3,305.92	3,224.96
	(c) Other current liabilities	379.64	327.32
	(d) Short-term provisions	12,258.19	11,993.22
	Sub-total - Current liabilities	25,023.14	21,981.16
	TOTAL - EQUITY AND LIABILITIES		
B	ASSETS		
1	Non-current Assets		
	(a) Fixed Assets	8,148.13	8,685.67
	(i) Tangible assets	208.08	229.92
	(ii) Intangible assets	894.87	516.84
	(iii) Capital work-in-progress		
	(iv) Intangible assets under development	1,068.77	1,068.77
	(b) Non-current investments	-	-
	(c) Deferred tax assets (net)	883.00	867.52
	(d) Long-term Loans and Advances	25.35	35.35
	(e) Other non-current assets	11,228.20	11,404.07
	Sub-total - Non-current assets		
2	Current assets	100.00	-
	(a) Current investments	4,844.08	4,511.35
	(b) Inventories	6,483.75	4,031.51
	(c) Trade Receivables	861.51	831.19
	(d) Cash and Cash Equivalents	1,505.60	1,203.04
	(e) Short-term Loans and Advances	-	-
	(f) Other current assets	13,794.94	10,577.09
	Sub-total - Current assets	25,023.14	21,981.16
	TOTAL - ASSETS		

NOTES :

- 1) The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
- 2) During the year under review paid up capital of the Company increased from Rs. 851.50 lacs to Rs. 903.94 lacs in view of allotment of 24433 equity shares on exercise of ESOP by some of the eligible employees and allotment of 500000 equity shares on preferential basis to non-promoters.
- 3) In terms of SEBI (ICDR) Regulations, 2009 the Board at its meeting held on 17th June, 2016 allotted 500000 Equity Shares on Preferential Basis to Non Promoters and 125000 Convertible Warrants to some of the Promoters of the Company. The proceeds received amounted to Rs. 2656.25 lacs. In terms of the Regulation 32 of the SEBI (LODR) Regulations, 2015 we state that there was no deviation of proceeds utilised for the period ended March, 2017 from the purposes mentioned in Private Placement Offer Letter.
- 4) The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10.05.2017.



For M. T. Ankleshwaria & Co.
Chartered Accountants

Madhu T. Ankleshwaria
Proprietor


Place : Mumbai

Date : 10 / 05 / 2017

By Order of the Board
For THEMIS MEDICARE LTD

[Signature]

Dr. SACHIN PATEL
(Managing Director & CEO)



M. T. ANKLESHWARIA & CO.
CHARTERED ACCOUNTANTS
MADHU T. ANKLESHWARIA
B.COM. (HONS) F.C.A.

TEL: 2614 9392
7, GOKUL NIWAS,
47, BAJAJ ROAD,
VILE PARLE (WEST),
MUMBAI - 400 056
mtankleshwaria@yahoo.com

Independent Auditor's Report

To
Board of Directors of
THEMIS MEDICARE LIMITED
Mumbai

1. We have audited the accompanying statement of **consolidated financial results** of Themis Medicare Limited (the 'Holding Company'), its subsidiaries, its associates and joint venture for the year ended 31st March, 2017 (the 'Statement of Consolidated Financial Results'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement of Consolidated Financial Results, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared on the basis of the related consolidated financial statements which is in accordance with the Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement of consolidated financial results.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement of Consolidated Financial Results are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement of the Consolidated Financial Results. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the statement of Consolidated Financial Results, whether due to fraud or error. In making in those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation and fair presentation of the Statement of Consolidated Financial Results in order to design the audit procedure that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as



well as evaluating the overall presentation of the Statement of the Consolidated Financial Results.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our Audit opinion.

3. We did not audit the financial statements / financial information of Two subsidiaries and One jointly controlled entities, whose financial statements / financial information reflect total assets of Rs.5947.00 lacs as at 31st March, 2017, total revenues of Rs.2921.88 lacs, net profit of Rs.130.00 lacs and the decrease in net cash flows amounting to Rs.481.66 lacs for the year ended on that date, as considered in the consolidated financial statements. The consolidated financial statements also include the Group's share of net profit of Rs.64.95 lacs for the year ended 31st March, 2017 as considered in the consolidated financial statements, in respect of Two associate Companies, whose financial statements / financial information have not been audited by us. These financial statements / financial information are unaudited except for one associate company and have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, jointly controlled entities and associates, is based solely on such unaudited financial statements / financial information and on the report from other auditors for one associate company.

Our opinion on the consolidated financial statements is not modified in respect of the above matters with respect to our reliance on the work done and the reports of other auditors wherever available and the financial statements / financial information certified by the Management.

In our opinion and to the best of our information and according to the explanations given to us these consolidated financial results:

- (i) Includes the results of the following entities:

List of Associates:

Long Island Nutritionals Private Limited
Gujarat Themis Biosyn Limited

Joint Venture: Richter Themis Medicare (I) Private Limited

Subsidiaries:

Themis Lifestyle Private Limited
Artemis Biotech Limited



(ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and

(iii) give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the Consolidated Net Profits and other financial information of the Company for the year ended March 31st 2017.

For **M.T.ANKLESHWARIA & CO,**
CHARTERED ACCOUNTANTS
Registration No. 100501W



A handwritten signature in black ink, appearing to read "Madhu T. Ankleshwaria".

MADHU T. ANKLESHWARIA
PROPRIETOR
Membership No. 30128

Place: Mumbai
Date: 10.05.2017

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.


Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

PART I (R in Lakhs)

Statement of Unaudited Financial Results for the year ended 31st March 2017.

		CONSOLIDATED				
	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Current Year ended	Previous year ended
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	(31/03/2016)
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	5,524.94	6,211.15	5,344.81	24,338.62	23,032.24
	(b) Other operating income	50.44	51.93	35.23	241.53	247.50
	Total income from operations (net)	5,575.38	6,263.08	5,380.04	24,580.15	23,279.74
2	Expenses					
	(a) Cost of materials consumed	1,632.09	1,726.90	1,540.31	6,793.12	7,093.21
	(b) Purchases of stock-in-trade	467.99	517.16	342.50	2,004.38	1,375.82
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(642.37)	173.90	32.18	(496.14)	266.16
	(d) Employee benefits expense	1,163.24	1,069.73	822.32	4,474.18	3,633.84
	(e) Depreciation and amortisation expense	306.88	183.00	333.44	970.43	1,112.30
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	2,175.52	2,066.72	1,727.91	8,061.18	6,938.07
	Total expenses	5,103.35	5,737.41	4,798.66	21,807.15	20,419.40
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	472.03	525.67	581.38	2,773.00	2,860.34
4	Other income	0.10	18.77	47.18	287.59	317.97
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	472.13	544.44	628.56	3,060.59	3,178.31
6	Finance costs	276.49	265.88	316.81	1,108.54	1,226.00
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	195.64	278.56	311.75	1,952.05	1,952.31
8	Exceptional items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	195.64	278.56	311.75	1,952.05	1,952.31
10	Tax expense	33.39	(36.13)	6.04	68.01	125.82
11	Net Profit / (Loss) from ordinary activities after tax (9 - 10)	162.25	314.69	305.71	1,884.04	1,826.49
12	Extraordinary items (net of tax expense Rs. NIL)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	162.25	314.69	305.71	1,884.04	1,826.49
14	Share of profit / (loss) of associates	(2.40)	41.74	15.53	64.95	105.80
15	Minority interest	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14 +15).	159.85	356.43	321.24	1,948.99	1,932.29
17	Paid-up equity share capital- Face Value Rs. 10/- each	903.94	903.13	851.50	903.94	851.50
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				10,985.84	6,551.18
19	Earnings per share (before extraordinary items)					
	(a) Basic	1.77	3.95	3.77	21.56	22.69
	(b) Diluted	1.72	3.84	3.74	21.01	22.51
19ii	Earnings per share (after extraordinary items)					
	(a) Basic	1.77	3.95	3.77	21.56	22.69
	(b) Diluted	1.72	3.84	3.74	21.01	22.51



PART II

Information for the year ended 31/03/2017

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended	Current Year ended	Previous year ended
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	(31/03/2016)
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	- Number of shares	2984138	2976005	2459705	2984138	2459705
	- Percentage of shareholding	33.01	32.95	28.89	33.01	28.89
2	Promoters and Promoter Group Shareholding					
	a) Pledged / Encumbered					
	- Number of shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
	b) Non - encumbered					
	- Number of shares	6055295	6055295	6055295	6055295	6055295
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	66.99	67.05	71.11	66.99	71.11

	Particulars	3 months ended (31/03/2017)
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-



THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

R IN LAKHS

Statement of Assets and Liabilities as at 31st March 2017		CONSOLIDATED	
	Particulars	As at 31/03/2017	As at 31/03/2016
		(Audited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share capital	903.94	851.50
	(b) Reserves and surplus	10,985.84	6,551.18
	(c) Amount Received against ESOP	156.25	-
	Sub-total - Shareholders' Funds	12,046.03	7,402.68
2	Non-current Liabilities		
	(a) Long-term borrowings	4,156.44	6,340.37
	(b) Deferred tax liabilities (net)	276.18	306.04
	(c) Other long-term liabilities	443.49	382.49
	(d) Long-term provisions	832.65	54.27
	Sub-total - Non-current Liabilities	5,708.76	7,083.17
3	Current Liabilities		
	(a) Short-term borrowings	5,409.30	5,188.42
	(b) Trade payables	3,514.74	3,490.30
	(c) Other current liabilities	3,801.86	3,704.12
	(d) Short-term provisions	496.39	582.86
	Sub-total - Current liabilities	13,222.29	12,965.70
	TOTAL - EQUITY AND LIABILITIES	30,977.08	27,451.55
B	ASSETS		
1	Non-current Assets		
	(a) Fixed Assets	11,902.42	12,314.87
	(b) Non-current investments	728.85	563.90
	(c) Long-term Loans and Advances	2,262.24	1,219.46
	(d) Other non-current assets	25.36	69.95
	Sub-total - Non-current assets	14,918.87	14,168.18
2	Current assets		
	(a) Inventories	6,433.98	5,826.44
	(b) Trade Receivables	7,038.37	4,757.33
	(c) Cash and Cash Equivalents	1,013.36	1,430.11
	(d) Short-term Loans and Advances	1,572.50	1,269.49
	Sub-total - Current assets	16,058.21	13,283.37
	TOTAL - ASSETS	30,977.08	27,451.55

NOTES :

- 1) The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
- 2) During the year under review paid up capital of the Company increased from Rs. 851.50 lacs to Rs. 903.94 lacs in view of allotment of 24433 equity shares on exercise of ESOP by some of the eligible employees and allotment of 500000 equity shares on preferential basis to non-promoters.
- 3) In terms of SEBI (ICDR) Regulations, 2009 the Board at its meeting held on 17th June, 2016 allotted 500000 Equity Shares on Preferential Basis to Non Promoters and 125000 Convertible Warrants to some of the Promoters of the Company. The proceeds received amounted to Rs. 2656.25 lacs. In terms of the Regulation 32 of the SEBI (LODR) Regulations, 2015 we state that there was no deviation of proceeds utilised for the period ended March, 2017 from the purposes mentioned in Private Placement Offer Letter.
- 4) The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10.05.2017.

For M. T. Ankleshwaria & Co.
Chartered Accountants

Madhu T. Ankleshwaria
Proprietor

By Order of the Board
For THEMIS MEDICARE LTD

Dr. SACHIN PATEL
(Managing Director & CEO)

Place : Mumbai
Date: 10 /05 /2017